当前位置:考试网  > 试卷库  > 学历类  > 自考  > 自考专业(建筑工程)  >  何谓应力集中?应力集中对钢材的机械性能有何影响?
试题预览

何谓应力集中?应力集中对钢材的机械性能有何影响?

查看答案
收藏
纠错
正确答案:

答:实际上钢结构构件中存在着孔洞、槽口、凹角、截面突然改变以及钢材内部缺陷,此时构件中的应力分布将不再保持均匀,而是在某些区域产生局部高峰应力,在另外一些区域则应力降低,形成所谓的应力集中。

答案解析:

暂无解析

你可能感兴趣的试题

当温度t<0℃时,随着温度下降,钢材的冲击韧性值也 ____________。

钢材所含化学成分中,需严格控制含量的有害元素为()

观测三角形三个内角后,将它们求和并减去180°所得的三角形闭合差为()

性能等级为4.6级和4.8级的C级普通螺栓连接,_____级的安全储备更大。

为提高轴心受压构件的整体稳定,在杆件截面面积不变的情况下,杆件截面的形式应使其面积分布()

热门试题 更多>
试题分类: 初级(写作)
练习次数:6次
试题分类: 写作
练习次数:0次
试题分类: 口语
练习次数:0次
试题分类: 理论与实务
练习次数:0次
1.The failure of a high-profile cholesterol drug has thrown a spotlight on the complicated machinery that regulates cholesterol levels.But many researchers remain confident that drugs to boost levels of 'good' cholesterol are still one of the most promising means to combat spiralling heart disease. 2.Drug company Pfizer announced on 2 December that it was cancelling all clinical trials of torcetrapib,a drug designed to raise heart-protective high-density lipoproteins (HDLs).In a trial of 15000 patients,a safety board found that more people died or suffered cardiovascular problems after taking the drug plus a cholesterol-lowering statin than those in a control group who took the statin alone. 3.The news came as a kick in the teeth to many cardiologists because earlier tests in animals and people suggested it would lower rates of cardiovascular disease."There have been no red flags to my knowledge," says John Chapman,a specialist in lipoproteins and atherosclerosis at the National Institute for Health and Medical Research (INSERM) in Paris who has also studied torcetrapib."This cancellation came as a complete shock." 4.Torcetrapib is one of the most advanced of a new breed of drugs designed to raise levels of HDLs,which ferry cholesterol out of artery-clogging plaques to the liver for removal from the body.Specifically,torcetrapib blocks a protein called cholesterol ester transfer protein (CETP),which normally transfers the cholesterol from high-density lipoproteins to low density,plaque-promoting ones.Statins,in contrast,mainly work by lowering the 'bad' low-density lipoproteins. Under pressure 5.Researchers are now trying to work out why and how the drug backfired,something that will not become clear until the clinical details are released by Pfizer.One hint lies in evidence from earlier trials that it slightly raises blood pressure in some patients.It was thought that this mild problem would be offset by the heart benefits of the drug.But it is possible that it actually proved fatal in some patients who already suffered high blood pressure.If blood pressure is the explanation,it would actually be good news for drug developers because it suggests that the problems are specific to this compound.Other prototype drugs that are being developed to block CETP work in a slightly different way and might not suffer the same downfall. 6.But it is also possible that the whole idea of blocking CETP is flawed,says Moti Kashyap,who directs atherosclerosis research at the VA Medical Center in Long Beach,California.When HDLs excrete cholesterol in the liver,they actually rely on LDLs for part of this process.So inhibiting CETP,which prevents the transfer of cholesterol from HDL to LDL,might actually cause an abnormal and irreversible accumulation of cholesterol in the body."You're blocking a physiologic mechanism to eliminate cholesterol and effectively constipating the pathway," says Kashyap.Going up 7.Most researchers remain confident that elevating high density lipoproteins levels by one means or another is one of the best routes for helping heart disease patients.But HDLs are complex and not entirely understood.One approved drug,called niacin,is known to both raise HDL and reduce cardiovascular risk but also causes an unpleasant sensation of heat and tingling.Researchers are exploring whether they can bypass this side effect and whether niacin can lower disease risk more than statins alone.Scientists are also working on several other means to bump up high-density lipoproteins by,for example,introducing synthetic HDLs."The only thing we know is dead in the water is torcetrapib,not the whole idea of raising HDL," says Michael Miller,director of preventive cardiology at the University of Maryland Medical Center,Baltimore. Questions 7-13 Match torcetrapib,HDLs,statin and CETP with their functions (Questions 8-13)..Write the correct letter A,B,C or D in boxes 8-13 on your answer sheet.NB You may use any letter more than once. 7.It has been administered to over 10,000 subjects in a clinical trial. 8.It could help rid human body of cholesterol. 9.Researchers are yet to find more about it. 10.It was used to reduce the level of cholesterol. 11.According to Kashyap,it might lead to unwanted result if it's blocked. 12.It produced contradictory results in different trials. 13.It could inhibit LDLs.List of choices A.TorcetrapicB.HDLSC.StatinD.CETP
试题分类: 阅读
练习次数:3次
扫一扫,手机做题